Clinical trials: Melanoma Stage III
Melanoma, Cancer
Perioperative Encobini in BRAFV600 Mutant Stage III (B/C/D) or Oligometastatic Stage IV Melanoma
A two-arm, randomised trial investigating the response of encorafenib and binimetinib compared to standard adjuvant therapy.
- Trial name
- PREMIUM (NCT05097378)
- Testing
- Encorafenib + Binimetinib, Standard Adjuvant Treatment
- Where
- United Kingdom
- Volunteers
- 18 people
- Sponsor
- CCTU- Cancer Theme
Metastatic Malignant Neoplasm in the Brain, Metastatic Melanoma
Nivolumab With Trametinib and Dabrafenib, or Encorafenib and Binimetinib in Treating Patients With BRAF Mutated Metastatic or Unresectable Stage III-IV Melanoma
This phase II trial studies the side effects and how well nivolumab with trametinib and dabrafenib, or encorafenib and binimetinib work in treating patients with BRAF-mutated stage III-IV melanoma that has spread to other places…
- Conditions
- Metastatic Malignant Neoplasm in the Brain, Metastatic Melanoma, Stage III Cutaneous Melanoma AJCC v7, Stage IIIA Cutaneous Melanoma AJCC v7
- Trial name
- NCT02910700
- Testing
- Binimetinib, Dabrafenib, Encorafenib
- Where
- United States
- Volunteers
- 52 people
- Sponsor
- M.D. Anderson Cancer Center
Stage III Malignant Melanoma of Skin AJCC V6, Stage IV Malignant Melanoma of Skin
Immunization With Autologous Dendritic Cells and Tumor Lysates in Melanoma Patients
Implementing this protocol has its ethical justification in that patients with metastatic melanoma, once tumor invasion has reached beyond the lymph node barrier, cannot possibly be treated satisfactorily with traditional surgery…
- Trial name
- NCT06152367
- Testing
- TAPCells vaccine
- Where
- Chile
- Volunteers
- 90 people
- Sponsor
- University of Chile
Stage IIIB Melanoma, Stage IIIC Melanoma
RO4929097 in Treating Patients With Stage IIIB, Stage IIIC, or Stage IV Melanoma That Can Be Removed by Surgery
This pilot phase II trial is studying how well RO4929097 works in treating patients with stage III, or stage IV melanoma that can be removed by surgery.
- Conditions
- Stage IIIB Melanoma, Stage IIIC Melanoma, Stage IV Melanoma
- Trial name
- NCT01216787
- Testing
- gamma-secretase/Notch signalling pathway inhibitor RO4929097, pharmacological study, therapeutic conventional surgery
- Where
- 2 sites in United States
- Sponsor
- National Cancer Institute (NCI)
Melanoma (Skin)
Study of Tumor Tissue Samples From Patients With Stage I, Stage II, or Stage III Malignant Melanoma
RATIONALE: Studying the genes expressed in samples of tumor tissue from patients with cancer may help doctors identify biomarkers related to cancer.
- Trial name
- NCT00991991
- Testing
- gene expression analysis, polymerase chain reaction, polymorphism analysis
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Case Comprehensive Cancer Center
Melanoma
Treatment Patterns and Outcomes Study in Patients With Unresectable Stage III and Metastatic (Stage IV) Melanoma in the United States
This study will collect real-world data from advanced melanoma diagnosis through most recent visit and data sourced from patient medical records following a 2-part study design consisting of a random sample (Part 1) and an…
- Trial name
- NCT03199846
- Testing
- Non-Interventional
- Where
- United States
- Volunteers
- 650 people
- Sponsor
- Bristol-Myers Squibb
Melanoma (Skin)
Vaccine Therapy and Resiquimod in Treating Patients With Stage II, Stage III, or Stage IV Melanoma That Has Been Completely Removed by Surgery
RATIONALE: Vaccines made from peptides may help the body build an effective immune response to kill tumor cells. Giving vaccine therapy together with resiquimod may make a stronger immune response and prevent or delay the…
- Trial name
- NCT00470379
- Testing
- resiquimod
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Mayo Clinic
Melanoma, Lymph Node Cancer
CMP-001 in Combo With Nivolumab in Stage IIIB/C/D Melanoma Patients With Clinically Apparent Lymph Node Disease
The purpose this research study is to determine if the combination of nivolumab and CMP-001 improves the likelihood of eradicating (destroying) disease in the lymph node (pathologic response rate).
- Trial name
- NCT03618641
- Testing
- CMP-001, Nivolumab
- Where
- United States
- Volunteers
- 34 people
- Sponsor
- Diwakar Davar
Melanoma (Skin)
Vaccine Therapy Plus Immune Adjuvants in Treating Patients With Advanced Melanoma
RATIONALE: Vaccines made from peptides that are found on melanoma cells may make the body build an immune response and kill melanoma cells.
- Trial name
- NCT00003362
- Testing
- QS21, gp100 antigen, incomplete Freund's adjuvant
- Where
- United States
- Sponsor
- Memorial Sloan Kettering Cancer Center
Recurrent Melanoma, Stage IA Skin Melanoma
Booster Vaccination in Preventing Disease Recurrence in Previously Vaccinated Patients With Melanoma That Has Been Removed By Surgery
This pilot clinical trial studies booster vaccination in preventing disease recurrence in previously vaccinated patients with melanoma that has been removed by surgery.
- Conditions
- Recurrent Melanoma, Stage IA Skin Melanoma, Stage IB Skin Melanoma, Stage IIA Skin Melanoma
- Trial name
- NCT01989559
- Testing
- gp100:209-217(210M) Peptide Vaccine, HPV 16 E7:12-20 Peptide Vaccine, Laboratory Biomarker Analysis
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- National Cancer Institute (NCI)
Metastatic Melanoma
Masitinib in Non-Resectable or Metastatic Stage 3/4 Melanoma Carrying a Mutation in the Juxta Membrane Domain of c-Kit
The objective is to assess the efficacy and safety of masitinib at 7.5 mg/kg/day in the treatment of patients with non-resectable or metastatic stage 3 or stage 4 melanoma carrying a mutation in the juxta membrane domain of c-Kit…
- Trial name
- NCT01280565
- Testing
- Masitinib, Dacarbazine
- Where
- 9 sites in United States, Czechia and 5 more
- Volunteers
- 134 people
- Sponsor
- AB Science
Melanoma (Skin)
Adenovirus CCL-21 Transduced MART-1/gp100/Tyrosinase/NY-ESO-1 Peptide-Pulsed Dendritic Cells Matured
RATIONALE: Vaccines made from gene-modified tumor cells may help the body build an immune response to kill tumor cells. PURPOSE: This phase I trial is studying the side effects and best dose of vaccine therapy in treating…
- Trial name
- NCT00798629
- Testing
- Autologous dendritic cell-adenovirus CCL21 vaccine
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Melanoma
A Phase III Study to Test the Benefit of a New Kind of Anti-cancer Treatment in Patients With Melanoma, After Surgical Removal of Their Tumor
The purpose of this clinical trial is to evaluate the benefit of the immunotherapeutic product GSK 2132231A in preventing disease relapse when given to melanoma patients, after surgical removal of their tumor.
- Trial name
- NCT00796445
- Testing
- GSK 2132231A
- Where
- 257 sites in United States, Argentina and 30 more
- Volunteers
- 1,351 people
- Sponsor
- GlaxoSmithKline
Melanoma
Novel Adjuvants for Peptide-Based Melanoma Vaccines
This is a study to determine the efficacy of a melanoma vaccine chemotherapy cocktail composed of CTLA-4 antibody; tyrosinase, gp100, and MART-1 peptides; and incomplete Freund's adjuvant (IFA) with or without interleukin-12 in…
- Trial name
- NCT00028431
- Testing
- MDX-CTLA4 Antibody; Tyrosinase/gp100/MART-1 Peptides Melanoma Vaccine
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- University of Southern California
Melanoma (Skin)
Combination Chemotherapy Plus Biological Therapy in Treating Patients With Metastatic Melanoma
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Biological therapies use different ways to stimulate the immune system and stop cancer cell from growing.
- Trial name
- NCT00004141
- Testing
- Cisplatin, dacarbazine, Granulocyte-macrophage colony-stimulating factor
- Where
- United States
- Volunteers
- 46 people
- Sponsor
- University of Chicago
Malignant Melanoma of Skin Stage III, Malignant Melanoma of Skin Stage IV
Vaccination With Autologous Dendritic Cells Loaded With Autologous Tumor Lysate or Homogenate Combined With Immunomodulating Radiotherapy and/or Preleukapheresis IFN-alfa in Patients With Metastatic Melanoma: a Randomized "Proof-of-principle" Phase II Study
Title: Vaccination with autologous dendritic cells loaded with autologous tumor lysate or homogenate combined with immunomodulating radiotherapy and/or preleukapheresis IFN-alfa in patients with metastatic melanoma: a randomized…
- Trial name
- ABSIDE (NCT01973322)
- Testing
- arm 1: DC Vaccine + RT, arm 2: DC Vaccine + IFN-alfa, arm 3: both arm 1 and 2 + RT
- Where
- Italy
- Volunteers
- 34 people
- Sponsor
- Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS
Acral Lentiginous Melanoma, Clinical Stage III Cutaneous Melanoma AJCC v8
A Study to Compare the Administration of Pembrolizumab After Surgery Versus Administration Both Before and After Surgery for High-Risk Melanoma
This phase II trial studies how pembrolizumab works before and after surgery in treating patients with stage III-IV high-risk melanoma.
- Conditions
- Acral Lentiginous Melanoma, Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8, Mucosal Melanoma
- Trial name
- NCT03698019
- Testing
- Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging
- Where
- 815 sites in United States
- Volunteers
- 313 people
- Sponsor
- National Cancer Institute (NCI)
Kidney Cancer, Melanoma (Skin)
Interleukin-2 Plus Bryostatin 1 in Treating Patients With Melanoma or Kidney Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Interleukin-2 may stimulate a person's white blood cells to kill tumor cells.
- Trial name
- NCT00006022
- Testing
- aldesleukin, bryostatin 1
- Where
- 2 sites in United States
- Volunteers
- 17 people
- Sponsor
- Virginia Commonwealth University
Advanced Hepatocellular Carcinoma, Advanced Melanoma
Multiple Adjunct Therapies to Improve Immunotherapy Treatment in Patients With Locally Advanced or Metastatic Melanoma or Advanced Hepatocellular Cancer
This clinical trial tests the effect of multiple therapies (propranolol, desloratadine, and magnesium and vitamin D supplements) added to primary standard of care immunotherapy (adjunct), as well as adjusting the timing of…
- Conditions
- Advanced Hepatocellular Carcinoma, Advanced Melanoma, Locally Advanced Melanoma, Metastatic Melanoma
- Trial name
- NCT07836712
- Testing
- Biospecimen Collection, Cholecalciferol, Computed Tomography
- Where
- United States
- Volunteers
- 46 people
- Sponsor
- University of Southern California
Recurrent Melanoma (Skin), Metastatic Melanoma
MC1R-targeted Alpha-particle Monotherapy and Combination Therapy Trial With Nivolumab in Adults With Advanced Melanoma
In this first-in human, phase I/IIa study, the safety and efficacy of [212Pb]VMT01, an alpha-particle emitting therapeutic agent targeted to melanocortin sub-type 1 receptor (MC1R) is being evaluated as a monotherapy and in…
- Conditions
- Recurrent Melanoma (Skin), Metastatic Melanoma, Melanoma Stage IV, Melanoma Stage III
- Trial name
- NCT05655312
- Testing
- [203Pb]VMT01, [212Pb]VMT01, Nivolumab
- Where
- 16 sites in United States
- Volunteers
- 300 people
- Sponsor
- Perspective Therapeutics